Lindynette (Ethinylestradiol, Gestodene)

Ethinylestradiol, the estrogen component, suppresses the hypothalamic‑pituitary‑ovarian axis, reducing the release of luteinising hormone and follicle‑stimulating hormone. This prevents the mid‑cycle surge that triggers ovulation, while also stabilising the endometrial lining.

The prescribed dose of Lindynette is determined by the treating physician. The product is supplied as a tablet containing 30 µg ethinylestradiol and 0.075 mg gestodene, and the prescriber will set the daily regimen based on clinical guidelines.

Lindynette is classified as Pregnancy Category X, meaning it must not be used during pregnancy because it can harm the fetus. It is also not recommended while breastfeeding, as hormones may pass into breast milk and affect the infant.

To order Lindynette, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lindynette combines a low‑dose estrogen (30 µg ethinylestradiol) with the progestogen gestodene, offering effective ovulation suppression with a relatively favorable bleeding profile. Compared with pills containing higher estrogen doses, it may have a lower risk of estrogen‑related side effects, while maintaining comparable contraceptive efficacy.

Lindynette tablets should be stored at ambient temperature, below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Lindynette is taken orally, once daily, at the same time each day. The tablet is swallowed with water and should be started according to the prescriber’s instructions, typically on the first day of the menstrual period or after a hormone‑free interval.

The most serious risks include venous thromboembolism, stroke, myocardial infarction and severe allergic reactions. These events are rare but can be life‑threatening, especially in women who smoke, have hypertension, a history of clotting disorders, or other cardiovascular risk factors.

Lindynette is contraindicated in women who are pregnant, breastfeeding, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, known or suspected estrogen‑dependent tumors, or who are over 35 and smoke cigarettes.